These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Hay KA Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609 [TBL] [Abstract][Full Text] [Related]
3. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. Freyer CW; Porter DL J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558 [TBL] [Abstract][Full Text] [Related]
4. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Chou CK; Turtle CJ Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497 [No Abstract] [Full Text] [Related]
5. Advances in CAR T Therapy for Hematologic Malignancies. Freyer CW; Porter DL Pharmacotherapy; 2020 Aug; 40(8):741-755. PubMed ID: 32383222 [TBL] [Abstract][Full Text] [Related]
6. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy. Walton ZE; Frigault MJ; Maus MV Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525 [TBL] [Abstract][Full Text] [Related]
7. Toxicities of CD19 CAR-T cell immunotherapy. Hirayama AV; Turtle CJ Am J Hematol; 2019 May; 94(S1):S42-S49. PubMed ID: 30784102 [TBL] [Abstract][Full Text] [Related]
8. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Siegler EL; Kenderian SS Front Immunol; 2020; 11():1973. PubMed ID: 32983132 [TBL] [Abstract][Full Text] [Related]
9. Critical care management of chimeric antigen receptor T-cell therapy recipients. Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616 [TBL] [Abstract][Full Text] [Related]
10. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Hughes AD; Teachey DT; Diorio C Semin Immunopathol; 2024 Jul; 46(3-4):5. PubMed ID: 39012374 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. Xiao X; Huang S; Chen S; Wang Y; Sun Q; Xu X; Li Y J Exp Clin Cancer Res; 2021 Nov; 40(1):367. PubMed ID: 34794490 [TBL] [Abstract][Full Text] [Related]
12. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K Front Immunol; 2021; 12():611366. PubMed ID: 33708205 [TBL] [Abstract][Full Text] [Related]
13. Reactions Related to CAR-T Cell Therapy. Miao L; Zhang Z; Ren Z; Li Y Front Immunol; 2021; 12():663201. PubMed ID: 33995389 [TBL] [Abstract][Full Text] [Related]
14. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies. Yang C; Nguyen J; Yen Y J Biomed Sci; 2023 Oct; 30(1):89. PubMed ID: 37864230 [TBL] [Abstract][Full Text] [Related]
16. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Brudno JN; Kochenderfer JN Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964 [TBL] [Abstract][Full Text] [Related]
17. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Gauthier J; Turtle CJ Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831 [TBL] [Abstract][Full Text] [Related]
18. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy. Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616 [TBL] [Abstract][Full Text] [Related]
19. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity. Jess J; Yates B; Dulau-Florea A; Parker K; Inglefield J; Lichtenstein D; Schischlik F; Ongkeko M; Wang Y; Shahani S; Cullinane A; Smith H; Kane E; Little L; Chen D; Fry TJ; Shalabi H; Wang HW; Satpathy A; Lozier J; Shah NN J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295816 [TBL] [Abstract][Full Text] [Related]
20. The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies. Zhang Q; Zhu X; Xiao Y Ann Hematol; 2024 Jul; 103(7):2197-2206. PubMed ID: 38329486 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]